Octave Bioscience raises $35.6M in Series C financing to boost its MSDA test and pipeline development for neurodegenerative diseases, supported by notable investors including Byers Capital and Novartis.
Amount Raised
$35.6 Million
Round Type
Series C
Menlo ParkBiotechnologyHealthcareInvestors
Description
Octave Bioscience has closed $35.6 million in Series C equity financing, supplemented by a $15.5 million term loan from Silicon Valley Bank. The funding will accelerate the commercialization of its flagship MSDA test for multiple sclerosis. With broad adoption already established, Octave aims to solidify its market position and advance its research pipeline. The round saw participation from a mix of new and existing investors.
Quick answer
Octave Bioscience raised $35.6 Million in a Series C round, dated September 4, 2025. Investors: Hikma Ventures, Intermountain Ventures, Valhalla Foundation, Novartis, Merck Global Health Innovation Fund, Casdin Capital, S32 and Northpond Ventures. Octave Bioscience is based in Menlo Park, California, United States.
- How much did Octave Bioscience raise?
- Octave Bioscience raised $35.6 Million in a Series C round on September 4, 2025.
- Who invested in Octave Bioscience?
- Hikma Ventures, Intermountain Ventures, Valhalla Foundation, Novartis, Merck Global Health Innovation Fund, Casdin Capital, S32 and Northpond Ventures are named as investors in this round.
- What does Octave Bioscience do?
- Octave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson’s Disease..
- Where is Octave Bioscience based and how big is it?
- Octave Bioscience is based in Menlo Park, California, United States. Fundz records about 83 employees.
- Who are the decision-makers at Octave Bioscience?
- Fundz holds 2 contacts at Octave Bioscience, including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Octave Bioscience that raised within 45 days of this round, from Fundz verified event records.
- Pelage Pharmaceuticals raised $120M (Series B) on October 15, 2025.
- ISOThrive raised $8.1M on October 10, 2025.
- Arthrosi Therapeutics raised $153M (Series E) on October 8, 2025.
- Axe Compute Inc. raised $51M on October 7, 2025.
- Cirius Therapeutics raised $800K (Seed) on October 7, 2025.
- Kernal Biologics raised $48M (Funding Round) on October 7, 2025.
Who to call at Octave Bioscience, and when
A new round usually means Octave Bioscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Octave Bioscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Octave Bioscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Octave Bioscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Octave Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Octave Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.